We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App





Cepheid Receives CE-IVD Registration for SARS-CoV-2, Flu A, Flu B and RSV Combination Test

By LabMedica International staff writers
Posted on 25 Nov 2020
Print article
Image: Xpert Xpress SARS-CoV-2, Flu A, Flu B and RSV Combination Test (Photo courtesy of Cepheid)
Image: Xpert Xpress SARS-CoV-2, Flu A, Flu B and RSV Combination Test (Photo courtesy of Cepheid)
Cepheid (Sunnyvale, CA, USA) has received the CE-IVD marking for its Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample.

The test, which received Emergency Use Authorization from the US Food & Drug Administration in September 2020, is now available in the European Union and other markets that recognize CE-IVD marking. The four-in-one test is designed for use on any of Cepheid's almost 30,000 GeneXpert Systems placed worldwide, with results delivered in approximately 36 minutes.

The GeneXpert System was built for simple, reference lab quality PCR testing – on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine. GeneXpert Systems are configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with 2 or 4 modules - meaning up to four different tests can be run at one time. The largest GeneXpert System is configured with up to 80 modules - meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.

"Things may get complicated this respiratory season as clinicians encounter a range of viral infections with symptoms overlapping with COVID-19, including Flu A, Flu B, and respiratory syncytial virus," said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "The ability to run a single, highly sensitive test that detects all four viruses in a syndromic panel provides actionable results and helps to alleviate pressure on our healthcare system."

"The dramatic impact of SARS-CoV-2 has been felt by us all, and we understand that a reliable supply of SARS-CoV-2 tests is critical to the communities our healthcare institutions serve - for the coming Flu season and beyond," said Cepheid President Warren Kocmond. "Another goal of the capacity expansion program is to ensure supply continuity of not only our 4-Plex combination test for SARS-CoV-2, Flu A&B and RSV, but the entire portfolio of critical tests Cepheid supplies - including tests for tuberculosis, MRSA, C. difficile, CT/NG, Strep A, and many more."



Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.